UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib Judith Meza-JuncoQuincy S.-C. ChuMichael B. Sawyer Mini Review 12 August 2009 Pages: 1 - 4
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines Dhana E. LarssonSadia HassanDan Granberg Original Article 19 April 2009 Pages: 5 - 12
PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin Zhu YuanFei YanXia Zhao Original Article 22 April 2009 Pages: 13 - 25
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck Byoung Chul ChoKi Chang KeumJoo Hang Kim Original Article 21 April 2009 Pages: 27 - 32
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors Josephia R. MuindiCandace S. JohnsonMarwan G. Fakih Original Article 26 April 2009 Pages: 33 - 40
ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress Adrienne N. HowardKathleen A. BridgesJoya Chandra Original Article 29 April 2009 Pages: 41 - 54
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate Punit H. MaratheAmrita V. KamathJoseph Fargnoli Original Article 26 April 2009 Pages: 55 - 66
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients Barrie R. CassilethNaiyer RizviMark G. Kris Original Article 07 May 2009 Pages: 67 - 71
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers Afshin DowlatiJames PoseyScot C. Remick Original Article 28 April 2009 Pages: 73 - 78
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer Noboru YamamotoTomohide TamuraNagahiro Saijo Original Article 26 April 2009 Pages: 79 - 88
Biological reactive intermediates that mediate dacarbazine cytotoxicity Jalal PourahmadMarzieh AmirmostofianJafar Shahraki Original Article 28 April 2009 Pages: 89 - 96
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Crystal S. DenlingerRebecca BlanchardPeter J. O’Dwyer Original Article 05 May 2009 Pages: 97 - 105
Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer Muhammad Wasif SaifK. I. SyrigosM. M. Shah Original Article 05 May 2009 Pages: 107 - 112
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer Junji FuruseTakuji OkusakaToshiya Sato Original Article 29 April 2009 Pages: 113 - 120
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors Zacharenia SaridakiPeriklis PappasDimitris Mavroudis Original Article 05 May 2009 Pages: 121 - 128
Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours Nobuyuki YamamotoNarikazu BokuHironobu Minami Original Article 13 May 2009 Pages: 129 - 136
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors Holly J. MeanyKatherine E. WarrenFrank M. Balis Original Article 09 May 2009 Pages: 137 - 142
The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway Takeshi AkiyoshiSumio MatznoKenji Matsuyama Original Article 16 May 2009 Pages: 143 - 150
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma Jen-Shi ChenYee ChaoYang-Chung Lin Original Article 20 May 2009 Pages: 151 - 157
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer Sung-Ji LeeSang-Hee ChoIk-Joo Chung Original Article 29 May 2009 Pages: 159 - 166
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies Chia-Chi LinMuralidhar BeeramAmita Patnaik Original Article 16 May 2009 Pages: 167 - 175
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent Amy W. ChunStephen C. CosenzaManoj Maniar Original Article 24 May 2009 Pages: 177 - 186
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature Jose OrtegaJ. Michael HayesScott Antonia Short Communication 21 August 2009 Pages: 187 - 190
The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer K. DredgeJ. A. KinkL. J. Marton Short Communication 15 August 2009 Pages: 191 - 195
K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment? Maria Giulia ZampinoElena MagniGiuseppe Renne Short Communication 02 September 2009 Pages: 197 - 199